|
|
|
Insider
Information: |
Baker Felix |
Relationship: |
Director, 10% Owner |
City: |
|
State: |
|
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
20 |
|
Direct
Shares |
927,207 |
|
Indirect Shares
|
141,861,898 |
|
|
Direct
Value |
$82,461,833 |
|
|
Indirect Value
|
$12,984,280,034 |
|
|
Total
Shares |
142,789,105 |
|
|
Total
Value |
$13,066,741,867 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
36
|
6
|
Stock
price went up :
|
15
|
6
|
Stock
price went down : |
21
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
6.0
|
Percentage
Gain/Loss : |
-24.3%
|
18.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Incyte Corp |
INCY |
Director, 10% Owner |
2023-09-29 |
559,963 |
2023-09-29 |
33,480,292 |
Premium* |
|
Ardea Biosciences Inc |
RDEA |
Director, 10% Owner |
2003-10-06 |
0 |
2012-02-01 |
116,454 |
Premium* |
|
Seagen Inc |
SGEN |
Director, 10% Owner |
2018-02-01 |
215,015 |
2018-02-01 |
44,355,335 |
Premium* |
|
Synageva BioPharma Corp |
GEVA |
Director, 10% Owner |
2015-06-22 |
100,503 |
2015-06-22 |
9,328,233 |
Premium* |
|
Viropharma Inc |
VPHM |
10% Owner |
2005-01-31 |
0 |
2011-12-14 |
303,264 |
Premium* |
|
Aceragen, Inc |
ACGN |
Director |
|
0 |
2017-07-03 |
145,453 |
Premium* |
|
Tapestry Pharmaceuticals Inc |
TPPHQ |
10% Owner |
|
0 |
2008-10-15 |
0 |
Premium* |
|
Genomic Health Inc |
GHDX |
Director, 10% Owner |
2012-10-01 |
288 |
2012-10-01 |
11,377,485 |
Premium* |
|
Allos Therapeutics Inc |
ALTH |
10% Owner |
|
0 |
2009-02-06 |
1,629 |
Premium* |
|
Biocryst Pharmaceuticals Inc |
BCRX |
10% Owner |
2016-08-16 |
46,918 |
2016-08-16 |
9,418,390 |
Premium* |
|
Heron Therapeutics Inc |
HRTX |
10% Owner |
|
0 |
2011-06-30 |
5,266,568 |
Premium* |
|
Adolor Corp |
ADLR |
10% Owner |
2010-04-26 |
0 |
2011-12-19 |
0 |
Premium* |
|
Diadexus Inc |
DDXS |
10% Owner |
|
0 |
2010-07-28 |
140,525 |
Premium* |
|
Pharmacyclics Inc |
PCYC |
10% Owner |
|
0 |
2011-08-22 |
1,809 |
Premium* |
|
Ocera Therapeutics Inc |
OCRX |
10% Owner |
2012-03-12 |
0 |
2012-03-14 |
57,704 |
Premium* |
|
XOMA Corporation |
XOMA |
Director, 10% Owner |
2012-10-29 |
0 |
2012-10-29 |
480,639 |
Premium* |
|
Neurogene |
NGNE |
10% Owner |
2015-08-07 |
4,520 |
|
0 |
Premium* |
|
Invitae Corp |
NVTA |
10% Owner |
|
0 |
2015-08-27 |
6,554,967 |
Premium* |
|
Bellicum Pharmaceuticals, Inc |
BLCM |
10% Owner |
|
0 |
2015-12-24 |
4,865,647 |
Premium* |
|
Kodiak Sciences Inc. |
KOD |
Director, 10% Owner |
2022-01-21 |
0 |
2022-06-06 |
15,967,504 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
1397 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 42 of 56
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
GHDX |
Genomic Health Inc |
Director |
|
2008-06-09 |
4 |
B |
$19.61 |
$303,149 |
I/I |
15,419 |
1,226,119 |
2.25 |
- |
|
BCRX |
Biocryst Pharmaceuticals ... |
10% Owner |
|
2008-11-20 |
4 |
B |
$1.00 |
$303,517 |
I/I |
303,517 |
4,309,994 |
1.5 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2008-03-13 |
4 |
B |
$7.93 |
$304,356 |
I/I |
38,404 |
7,690,417 |
2.25 |
- |
|
ALTH |
Allos Therapeutics Inc |
10% Owner |
|
2009-02-04 |
4 |
S |
$8.01 |
$305,386 |
I/I |
(36,586) |
228,113 |
0 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2005-04-29 |
4 |
B |
$3.99 |
$307,022 |
I/I |
76,759 |
228,556 |
2.25 |
- |
|
ACGN |
Aceragen, Inc |
10% Owner |
|
2007-11-07 |
4 |
S |
$12.66 |
$308,642 |
I/I |
(24,383) |
575,768 |
0 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2011-12-30 |
4 |
OE |
$6.25 |
$309,769 |
I/I |
49,563 |
450,461 |
0 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2006-06-28 |
4 |
B |
$4.02 |
$310,726 |
I/I |
77,345 |
1,372,718 |
2.25 |
- |
|
ACGN |
Aceragen, Inc |
10% Owner |
|
2007-11-15 |
4 |
S |
$11.77 |
$311,031 |
I/I |
(26,415) |
1,100,592 |
0 |
- |
|
ACGN |
Aceragen, Inc |
10% Owner |
|
2007-12-06 |
4 |
S |
$12.35 |
$311,323 |
I/I |
(25,202) |
1,004,905 |
0 |
- |
|
KOD |
Kodiak Sciences Inc. |
Director |
|
2022-02-15 |
4 |
B |
$54.16 |
$314,099 |
I/I |
5,800 |
14,369,871 |
2.25 |
% |
|
SGEN |
Seagen Inc |
Director |
|
2005-03-23 |
4 |
B |
$4.96 |
$314,315 |
I/I |
63,376 |
133,975 |
2.25 |
- |
|
VPHM |
Viropharma Inc |
10% Owner |
|
2006-02-28 |
4 |
S |
$19.90 |
$315,218 |
I/I |
(15,707) |
103,540 |
|
- |
|
INCY |
Incyte Corp |
Director |
|
2011-12-01 |
4 |
B |
$13.78 |
$315,958 |
I/I |
22,380 |
288,767 |
2.25 |
- |
|
RDEA |
Ardea Biosciences Inc |
10% Owner |
|
2007-12-19 |
4 |
B |
$13.25 |
$317,576 |
I/I |
23,968 |
43,108 |
1.5 |
- |
|
INCY |
Incyte Corp |
Director |
|
2008-12-19 |
4 |
B |
$3.60 |
$321,154 |
I/I |
89,241 |
3,475,840 |
2.25 |
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2012-03-02 |
4 |
B |
$29.52 |
$323,899 |
I/I |
10,972 |
1,461,872 |
2.25 |
- |
|
KOD |
Kodiak Sciences Inc. |
Director |
|
2022-01-25 |
4 |
B |
$58.90 |
$323,934 |
I/I |
5,500 |
14,027,837 |
2.25 |
% |
|
SGEN |
Seagen Inc |
Director |
|
2005-04-29 |
4 |
B |
$3.99 |
$326,985 |
I/I |
81,750 |
346,523 |
2.25 |
- |
|
VPHM |
Viropharma Inc |
10% Owner |
|
2010-04-29 |
4 |
B |
$12.98 |
$328,600 |
I/I |
25,243 |
229,394 |
1.5 |
- |
|
INCY |
Incyte Corp |
10% Owner |
|
2003-09-22 |
4 |
B |
$4.97 |
$329,617 |
I/I |
66,300 |
1,479,155 |
1.5 |
- |
|
RDEA |
Ardea Biosciences Inc |
10% Owner |
|
2006-12-26 |
4 |
B |
$4.00 |
$331,992 |
I/I |
82,998 |
854,210 |
1.5 |
- |
|
INCY |
Incyte Corp |
Director |
|
2008-01-11 |
4 |
B |
$10.94 |
$335,548 |
I/I |
30,682 |
5,393,032 |
2.25 |
- |
|
ALTH |
Allos Therapeutics Inc |
10% Owner |
|
2007-06-21 |
4 |
S |
$5.55 |
$342,460 |
I/I |
(61,690) |
6,011,855 |
0 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2009-05-20 |
4 |
B |
$9.72 |
$342,659 |
I/I |
35,253 |
400,898 |
2.25 |
- |
|
1397 Records found
|
|
Page 42 of 56 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|